1-4 of 4
Laura Biganzoli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Ian Krop, Vandana Abramson, Marco Colleoni, Tiffany Traina, Frankie Holmes, Laura Garcia-Estevez, Lowell Hart, Ahmad Awada, Claudio Zamagni, Patrick G. Morris, Lee Schwartzberg, Stephen Chan, Ayca Gucalp, Laura Biganzoli, Joyce Steinberg, Lorenzo Sica, Maureen Trudeau, Denka Markova, Jamal Tarazi, Zhou Zhu, Thomas O'Brien, Catherine M. Kelly, Eric Winer, Denise A. Yardley
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6149–6157.
https://doi.org/10.1158/1078-0432.CCR-20-1693
Published: 01 December 2020
View article titled, A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Open the PDF for A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View article titled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <em>AKT1</em><sup>E17K</sup>-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial

Amelia McCartney, Martina Bonechi, Francesca De Luca, Chiara Biagioni, Giuseppe Curigliano, Erica Moretti, Alessandro Marco Minisini, Mattias Bergqvist, Matteo Benelli, Ilenia Migliaccio, Francesca Galardi, Emanuela Risi, Irene De Santo, Dario Romagnoli, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2131–2139.
https://doi.org/10.1158/1078-0432.CCR-19-3271
Published: 01 May 2020
View article titled, Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
Open the PDF for Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial in another window
Includes: Supplementary data
Journal Articles

Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population

Christopher D. Hart, Alessia Vignoli, Leonardo Tenori, Gemma Leonora Uy, Ta Van To, Clement Adebamowo, Syed Mozammel Hossain, Laura Biganzoli, Emanuela Risi, Richard R. Love, Claudio Luchinat, Angelo Di Leo
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (6): 1422–1431.
https://doi.org/10.1158/1078-0432.CCR-16-1153
Published: 14 March 2017
View article titled, Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
Open the PDF for Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population in another window
Includes: Supplementary data